In the last decade, T2DM therapy has shifted with the advent of sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists as these agents have shown significant cardioprotective and renoprotective benefits in large-scale cardiovascular outcome trials (CVOTs) [4]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.